Synageva's LAL deficiency drug wins breakthrough designation from FDA

05/21/2013 | American City Business Journals

The FDA granted breakthrough therapy status to Synageva BioPharma's experimental drug sebelipase alfa, or SBC-102, as a treatment for early onset lysosomal acid lipase deficiency, also known as Wolman disease. The drug is currently in clinical trials against both early onset and late onset LAL deficiency. Sebelipase alfa previously won orphan designation and fast track status from the FDA.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC